Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9881972 | 0.86 | PIM1 (0.53) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9881936 | 0.83 | PRKCA (0.64) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9881979 | 0.83 | PIM1 (0.51) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9881967 | 0.82 | PIM1 (0.64) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9881971 | 0.82 | PIM1 (0.63) | PIM1PIM3PIM2LRRK2PRKCA | |
| SCHEMBL9882004 | 0.80 | PIM1 (0.64) | PIM1PIM3PIM2 | |
| SCHEMBL9881926 | 0.79 | PIM1 (0.65) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9882013 | 0.77 | PRKCQ (0.68) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9881957 | 0.77 | PRKCQ (0.68) | PIM1PIM3PIM2PRKCAPRKCQ | |
| SCHEMBL9882007 | 0.77 | PIM1 (0.66) | PIM1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-8569337-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885FLT3 160/4885CDK1 124/4885 |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885FLT3 160/4885CDK1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.